Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
June 28, 2023 04:00 ET
|
AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
June 28, 2023 04:00 ET
|
AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Thermosome Announces Participation in IMAGIO Consortium to Improve Cancer Treatment
June 20, 2023 04:00 ET
|
AKAMPION
IMAGIO consortium of clinical partners coordinated by Philips receives EUR 24 million grant from the Innovative Health Initiative (IHI) and additional funding from industry partners to support the...
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
June 20, 2023 04:00 ET
|
AKAMPION
Data presented at the 24th EFFORT Congress in Vienna (Austria) Leipzig, Germany, June 20, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using...
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
May 30, 2023 05:00 ET
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
May 30, 2023 04:00 ET
|
AKAMPION
Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...
Thermosome Announces First Patient Dosed in Phase I Trial with Lead Program THE001
May 24, 2023 04:00 ET
|
AKAMPION
- Addressing high unmet medical need in locally advanced soft tissue sarcoma- Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
May 24, 2023 04:00 ET
|
AKAMPION
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
May 12, 2023 04:00 ET
|
AKAMPION
ROTTERDAM, May 12, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the...
Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
May 09, 2023 03:30 ET
|
AKAMPION
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...